We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Revolutionary Blood Test Detects 30 Different Types of Cancers with 98% Accuracy

By LabMedica International staff writers
Posted on 29 Apr 2025

With cancer expected to become the leading cause of global mortality by 2030, early detection remains the most effective strategy to reduce death rates. More...

Current screening methods only cover five types of cancer and are hindered by high false-positive rates. Now, a new blood test has the potential to detect 30 different types of cancer, including pancreatic, lung, and ovarian cancers, with an average accuracy of 98.4%.

The study, conducted by a multi-institutional research team led by HCG Manavata Cancer Centre (HCGMCC, Nashik, India), employed a novel serum metabolome-based diagnostic platform powered by machine learning to identify specific metabolic signatures linked to cancer. Unlike other multi-cancer early detection (MCED) tests that depend on detecting tumor DNA or cells, which are often limited by low biomarker concentrations, this new test focuses on capturing changes in metabolites. This provides a more reliable and sensitive result, particularly for detecting cancers at early stages. Published in Cancer Reports, the study included 6,445 participants, including over 2,800 confirmed, treatment-naïve cancer patients across four stages of the disease. Serum samples were analyzed using high-resolution mass spectrometry, and the data were processed through a proprietary Cancer Detection Artificial Intelligence (CDAI) algorithm. The platform demonstrated consistently high sensitivity, even in early-stage (Stage I/II) cancers, a feat that current diagnostic methods rarely achieve.

The test, which profiles more than 8,000 metabolites in blood serum, exhibited near-perfect accuracy across all stages (I–IV) and age groups (20 to 80+ years). Significantly, it identified Stage I cancers with 98.9% sensitivity, filling a crucial gap in oncology, where most cancers are diagnosed too late for effective treatment. The model's robustness was confirmed across various age groups, maintaining detection sensitivity above 96% across all demographics and cancer stages. Plans are currently in progress to initiate larger, multi-center clinical trials, with the goal of eventually bringing the test to commercial use. Efforts are also underway to integrate tissue-of-origin prediction capabilities, which would further assist physicians in initiating accurate follow-up diagnostics and treatment strategies.

“The new test, validated in a single-blinded trial, reduces over-diagnosis risks while expanding coverage to thirty malignancies,” said Dr. Raj Nagarkar, Managing Director and Chief of Surgical Oncology and Robotic Services, HCGMCC, who led the research team. “We believe this test has the potential to redefine cancer screening, especially in low- and middle-income countries like India. Its scalability, accuracy and ability to detect cancers early could enable Governments and healthcare providers to offer timely intervention, which ultimately saves lives and reduces the cost burden of late-stage treatment.”

Related Links:
HCGMCC


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.